OVERVIEW OF ACTIVITY

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10% of all hematologic cancers. The American Cancer Society estimated that 21,700 new cases of MM will be diagnosed in the United States in 2012, with an estimated 10,710 deaths. The development of molecular-targeted agents and alternative chemotherapeutics for the treatment of MM has been the focus of extensive research and has resulted in the emergence of clinical scenarios in which multiple treatment options may be available. The treatment of MM and the symptoms associated with the disease have improved dramatically over the past decade, particularly with the advent of novel agents, and the budding landscape surrounding the optimal management of MM is exciting and complex. Knowledge of the many therapeutic advances and changing practice standards is necessary to ensure optimal patient outcomes. To bridge the gap between research and patient care, this activity designed specifically for the practicing oncology nurse features discussions with leading hematologic oncology investigators and their nursing counterparts. By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist registered oncology nurses, clinical nurse specialists and nurse practitioners with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with MM.

LEARNING OBJECTIVES

• Discuss the benefits and risks associated with evidence-based systemic therapies used in the treatment of MM, including chemotherapy, proteasome inhibitors, corticosteroids and immunomodulatory agents, in the pre- and postautologous stem cell transplant (ASCT) settings and for patients who are not candidates for ASCT.
• Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
• Evaluate the preliminary safety profiles and response outcomes observed in studies of next-generation proteasome inhibitors and immunomodulatory agents for relapsed or refractory and previously untreated MM.

ACCREDITATION STATEMENT

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CREDIT DESIGNATION STATEMENT

This educational activity for 1.5 contact hours is provided by Research To Practice during the period of August 2012 through August 2013.

HOW TO USE THIS CNE ACTIVITY

This is an audio CNE program. This website contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form, as well as links to relevant abstracts and full-text articles.

To receive credit, participants should read the learning objectives and faculty disclosures, listen to the audio MP3s and complete the Post-test and Educational Assessment and Credit Form located at ResearchToPractice.com/ONSMM2012/CNE. A statement of CNE credit will be issued only upon completion of the Post-test, with a score of 75% or better, and the Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Melissa Alsina, MD
Head, Multiple Myeloma Program
Associate Professor
Department of Blood and Marrow Transplantation
Moffitt Cancer Center
Tampa, Florida

Advisory Committee: Millennium: The Takeda Oncology Company; Paid Research: Celgene Corporation, Millennium: The Takeda Oncology Company.

Beth Faiman, PhDc, MSN, APRN-BC, AOCN
Pre-Doctoral Research Candidate
Case Western Reserve University
Nurse Practitioner, Taussig Cancer Institute
The Cleveland Clinic
Cleveland, Ohio

Advisory Committee and Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company.

Rafael Fonseca, MD
Getz Family Professor of Cancer
Chair, Department of Internal Medicine
Associate Director
Center for Individualized Medicine
Mayo Clinic Arizona
Scottsdale, Arizona

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Intellikine, Lilly USA LLC, Medtronic Inc, Millennium: The Takeda Oncology Company, Otsuka Pharmaceutical Co Ltd; Research Support: Celgene Corporation, Cylene Pharmaceuticals, Onyx Pharmaceuticals Inc.

Kena C Miller, MSN, FNP-BC
Advanced Registered Nurse Practitioner
Department of Medicine
Mayo Clinic
Jacksonville, Florida

Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company; Speakers Bureau: Millennium: The Takeda Oncology Company.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Onyx Pharmaceuticals Inc.

Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.